BerGenBio
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including cancer and severe respiratory infections. AXL: a promising target to treat life-threatening diseases The tyrosine kinase target AXL is known to play an important role in both the innate and adaptive immune systems, BerGenBio is developing two highly selective AXL inhibitors bemcentinib and tilvestamab. Business model: R&D excellence and strategic partnerships BerGenBio is leveraging its solid leadership position in understanding the role of AXL and related kinase signalling in diseases of high unmet need to develop a diversified pipeline of selective AXL inhibitors.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-03 19:22 |
Regulatory News Service
BerGenBio ASA: Update on Strategic Review Process and Status of Activities
|
English | 2.6 KB | |
| 2025-06-03 15:55 |
General Meeting Notice
BerGenBio ASA: Notice of Annual General Meeting - Attachment: Notice_of_AGM_Ber…
|
Norwegian | 424.8 KB | |
| 2025-06-03 15:55 |
General Meeting Notice
BerGenBio ASA: Notice of Annual General Meeting
|
English | 2.6 KB | |
| 2025-04-30 07:51 |
Regulatory News Service
Financial calendar
|
English | 666 bytes | |
| 2025-04-29 20:03 |
Annual Report
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Rep…
|
English | 3.9 MB | |
| 2025-04-29 20:03 |
Annual Report
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Rep…
|
English | 2.8 MB | |
| 2025-04-29 20:03 |
Annual Report
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Rep…
|
English | 2.6 KB | |
| 2025-03-26 06:00 |
Regulatory News Service
BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in re…
|
English | 3.9 KB | |
| 2025-03-17 06:00 |
Regulatory News Service
BerGenBio announces advancement of its strategic review
|
English | 2.8 KB | |
| 2025-02-26 06:00 |
Earnings Release
BerGenBio Fourth Quarter Results 2024
|
English | 926.7 KB | |
| 2025-02-26 06:00 |
Earnings Release
BerGenBio Fourth Quarter Results 2024
|
English | 4.9 KB | |
| 2025-02-25 18:58 |
Regulatory News Service
BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of…
|
English | 4.5 KB | |
| 2025-02-25 18:58 |
Regulatory News Service
BerGenBio avslutter 1L STK11m NSCLC-studie og vil utforske strategiske alternat…
|
Norwegian | 4.5 KB | |
| 2025-02-24 07:13 |
Transaction in Own Shares
BerGenBio - Disclosure of shareholding
|
English | 702 bytes | |
| 2025-02-18 06:00 |
Earnings Release
BerGenBio ASA: Invitation to fourth quarter 2024 results webcast
|
English | 2.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Vivoryon Therapeutics N.V. | Germany | VVY | |
|
Vytrus Biotech S.A. | Spain | VYT | |
|
WntResearch AB | Sweden | WNT | |
|
Xbrane Biopharma | Sweden | XBRANE | |
|
Xintela AB | Sweden | XINT | |
|
XTL Biopharmaceuticals Ltd. | Israel | XTLB | |
|
Zealand Pharma | Denmark | ZEAL | |
|
Zelluna ASA | Norway | ULTI | |
|
Zephyrus Wing Energies Ltd. | Israel | ZPRS | |
|
Ziccum AB | Sweden | ZICC |